Immunohistochemical Expression of KI-67 and P53 in Cervical Carcinoma: Correlation with Prognostic Clinicopathological Features
References
- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021.
- International Agency for Research on Cancer. Global Cancer Observatory. Cancer today: WHO; 2022 [Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf.
- Lee MY, Shen MR. Epithelial-mesenchymal transition in cervical carcinoma. Am J Transl Res. 2012;4(1):1-13
- Bullwinkel J, Baron-Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol. 2006 Mar;206(3):624–35.
- Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 1992 Jan;25(1):31–40.
- Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
- Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13–27.
- Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002;40:2–11.
- Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In Blaustein’s Pathology of the Female Genital Tract, RJ Kurman (ed.). 1994; 244–246
- Bulten J, Van der Laak JA, Gemmink JH, Pahlplatz MM, De Wilde PC, Hanselaar AG. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. J Pathol 1996; 178: 268–273
- Van Leeuwen AM, Pieters WJ, Hollema H, Burger MP. Atypical mitotic figures and the mitotic index in CIN. Virchows Arch 1995; 427: 139–144
- Pieters WJ, Koudstaal J, Ploem-Zaayer JJ, Janssens J, Oosterhuis JW. The three-group metaphase as a morphologic indicator of high-ploidy cells in cervical intraepithelial neoplasia. Anal Quant CytolHistol 1992; 14: 227–232
- Shurbaji MS, Brooks SK, Thurmond MS. Proliferating cell nuclear antigen immunoreactivity in cervical intraepithelial neoplasia and benign cervical epithelium. Am J Clin Pathol 1993
- Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2013;7:57–68.
- Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–9
- Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R: Cancer of the cervix uteri: 2021 update. Int J GynaecolObstet. 2021, 155 Suppl 1:28-44
- Höhn A, Brambs C, Hiller G, May D, Schmoeckel E, Horn L-C. Tumours of the uterine cervix 2020 WHO Classification of Female Genital Tumors. 812021. p. 1145-53.
- Thompson EF, Chen J, Huvila J, Pors J, Ren H, Ho J, Chow C, Ta M, Proctor L, mcalpine JN, Huntsman D, Gilks CB, Hoang L. P53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. Mod Pathol. 2020 Sep;33(9):1649-1659. Doi: 10.1038/s41379-020-0527-y. Epub 2020 Apr 1. PMID: 32238876.
- R D, Arunachalam S, Amitkumar K, John JJ, Sudalaimuthu M. An Immunohistochemical Study on Ki-67 Expression in Squamous Cell Carcinomas of Cervix With Clinicopathological Correlation. Cureus 2023;15
- Dinu A, Aschie M, Cozaru GC, Mitroi AF, Grasa CN, Iordache IE, Deacu M, Orasanu CI, Nicolau AA, Baltatescu GI. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis? J Gastrointestin Liver Dis. 2023 Jun 22;32(2):162-169. Doi: 10.15403/jgld-4654. PMID: 37345605.
- Patel A, Galaal K, Burnley C, et al.: Cervical cancer incidence in young women: a historical and geographiccontrolled UK regional population study. Br J Cancer. 2012, 106:1753-9
- Gravdal BH, Lönnberg S, Skare GB, Sulo G, Bjørge T: Cervical cancer in women under 30 years of age in Norway: a population-based cohort study. BMC Womens Health. 2021, 21:110
- Wright JD, Matsuo K, Huang Y, et al.: Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstet Gynecol. 2019, 134:49-57.
- Gogoi PK, Borgohain M, Sonowal R: Ki-67 expression and apoptotic index in premalignant and malignant lesions of uterine cervix. Int J Contemp Med Res. 2016, 3:3401-5.
- Zhong P, Li J, Gu Y, Liu Y, Wang A, Sun Y, Lu L: P16 and Ki-67 expression improves the diagnostic accuracy of cervical lesions but not predict persistent high risk human papillomavirus infection with CIN1. Int J Clin Exp Pathol. 2015, 8:2979-86.
- Chen HH, Meng WY, Li RZ, et al.: Potential prognostic factors in progression-free survival for patients with cervical cancer. BMC Cancer. 2021, 21:531
- Wu Y, Lv M, Qian T, Shen Y: Correlation analysis of Ki67 and CK7 expression with clinical characteristics and prognosis of postoperative cervical adenocarcinoma patients. Ann Palliat Med. 2021, 10:9544-52
- Ramesh A, Chander RV, Srinivasan C, Vengadassalapathy S. Prevalence of Angiogenesis, Proliferation, and Apoptosis Markers of Cervical Cancer and Their Correlation with Clinicopathological Parameters. Journal of Oncology 2020;2020:8541415.
- Elsokary, A. N., Attiah, S. M., Ghannam, B. B. Immunohistochemical Study of CDK5 and Ki-67 in Cervical Precancerous Lesion and Carcinoma. The Egyptian Journal of Hospital Medicine, 2019; 74(2): 270-276.
- Bahnassy AA, Zekri AR, Alam El-Din HM, Aboubakr AA, Kamel K, El-Sabah MT, Mokhtar NM: The role ofcyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. J Egypt NatlCanc Inst. 2006, 18:292-302.
- Kubik S, Jesionek-Kupnicka D, Stawiski K, Fijuth J, Moszyńska-Zielińska M, Kuncman L, et al. Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma. Journal of Obstetrics and Gynaecology 2022;42:2248–54.
- Ancuţa E, Ancuţa C, Cozma LG, et al.: Tumor biomarkers in cervical cancer: focus on Ki-67 proliferationfactor and E-cadherin expression. Rom J MorpholEmbryol. 2009, 50:413-8
- Raju K, Punnayanapalya SS, Mariyappa N: Significance of p53, pRb and Ki-67 markers in cervicalintraepithelial lesion and malignancy. Biomed Res Ther. 2015, 2:374-84
- Silva-Filho AL, Bruno BN, da Silva LB, Traiman P, de Castro e Silva JG, et al. Associação entre aexpressão das proteínas p53 e Ki-67 e osachadosclínicopatológicosempacientes com carcinoma invasor do colouterino. RevistaBrasileira de Ginecologia e Obstetrícia 2005;27:243–7
- Gallardo-Alvarado L, Cantú-de León D, Ramirez-Morales R, et al.: Tumor histology is an independent prognostic factor in locally advanced cervical carcinoma: a retrospective study. BMC Cancer. 2022, 22:401.
- Brambs CE, Höhn AK, Hentschel B, Fischer U, Bilek K, Horn LC: The prognostic impact of grading in FIGO IB and IIB squamous cell cervical carcinomas. GeburtshilfeFrauenheilkd. 2019, 79:198-204.
- Matsuo K, Mandelbaum RS, Machida H, Purushotham S, Grubbs BH, Roman LD, Wright JD: Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol. 2018, 29:e91.
- Wong WSF, McGuire LJ. Tumor growth fraction in cervical carcinoma. Gynecol Oncol. 1991 Jan;40(1):48–54
- Zhang T, Zhao C, Chen D, Zhou Z: Overexpression of AQP5 in cervical cancer: correlation withclinicopathological features and prognosis. Med Oncol. 2012, 29:1998-2004
- Tantari M, Bogliolo S, Morotti M, Balaya V, Bouttitie F, Buenerd A, et al. Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study. Cancers 2022;14:212.
- Choi Y, Ando Y, Lee D, Kim NY, Lee OE, Cho J, et al. Profiling of Lymphovascular Space Invasion in Cervical Cancer Revealed PI3K/Akt Signaling Pathway Overactivation and Heterogenic Tumor-Immune Microenvironments 2023;13.
- Sung, YN., Kim, D. & Kim, J. p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations. DiagnPathol 17, 92 (2022)
- de Haan LM, de Groen RAL, de Groot FA, Noordenbos T, van Wezel T, van Eijk R, Ruano D, Diepstra A, Koens L, Nicolae-Cristea A, Hartog WCED, Terpstra V, Ahsmann E, Dekker TJA, Sijs-Szabo A, Veelken H, Cleven AHG, Jansen PM, Vermaat JSP. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas. Virchows Arch. 2024 Oct;485(4):643-654
- Tessier-Cloutier B, Kortekaas KE, Thompson E, Pors J, Chen J, Ho J, Prentice LM, McConechy MK, Chow C, Proctor L, McAlpine JN, Huntsman DG, Gilks CB, Bosse T, Hoang LN. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol. 2020;33(8):1595-1605.
- Jia H, Wu S, Ma G, Yang P, Li X, Zeng M, Ji X, Xing X. p53 immunohistochemistry staining patterns and prognosis significance in 212 cases of non-endometrioid endometrial cancer. Pathol Res Pract. 2024;263:155595.
- Thompson EF, Chen J, Huvila J, Pors J, Ren H, Ho J, Chow C, Ta M, Proctor L, McAlpine JN, Huntsman D, Gilks CB, Hoang L. p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. Mod Pathol. 2020 Sep;33(9):1649-1659
- Freier, C. P., Stiasny, A., Kuhn, C., Mayr, D., Alexiou, C., Janko, C., Wiest, I., Jeschke, U., &Kost, B. (2016). Immunohistochemical Evaluation of the Role of p53 Mutation in Cervical Cancer: Ser-20 p53-Mutant Correlates with Better Prognosis. AnticancerResearch, 36(6), 3131–3137
- Tan G, Sharifah N, Salwati S, Hatta A, Shiran M, Ng H. Immunohistochemical study of p53 expression in premalignant and malignant cervical neoplasms Med Health. 2007;2:125–32
- Skopelitou A, Kamina S, Krikoni O, Agnantis NJ. p53 DO-1 immunohistochemical overexpression in premalignant and malignant cervical lesions. Anticancer Research 1997;17:269–75
- Stoenescu TM, Ivan LD, Stoenescu N, Azoicăi D. (Assessment tumor markers by immunohistochemistry (Ki67, p53 and Bcl-2) on a cohort of patients with cervical cancer in various stages of evolution). Revista Medico-chirurgicala a Societatii de Medici siNaturalisti din Iasi. 2011 Apr-Jun;115(2):485-492
- Vemula S, Mucharla R. Study of p53 expression in Carcinoma Cervix and Normal Cervical Epithelium with clinical correlation. Global Journal for Research Analysis 2021:28–32
- Horn L-C, Fischer U, Hänel C, Kuhn H, Raptis G, Bilek K. p53 in Surgically Treated and Pathologically Staged Cervical Cancer: Correlation with Local Tumor Progression, But Not with Lymphatic Spread. Pathology Research and Practice 2001;197:605–9
- Singh S, Malukani K, Singh Chauhan S, Agrawal Saini P, Kumar Mishra P. Study on p53 Expression in Carcinoma Cervix and its Correlation with Clinical Parameters, Grading and Staging: A Cross-Sectional Study. Res J Med Sci. 2024;18(5):620–624.
- Mastutik G, Rahniayu A, Kurniasari N, Rahaju AS, Alia R, Mustokoweni S. The Expression of E6 HPV, P53 and P16ink4a at Well, Moderately, and Poorly Differentiated Cervical Adenocarcinoma 2020;55:295–300
- Gahine R, Pandey V, Mehta S. Analysis of pattern of expression of immunohistochemical markers p16, p53, and Ki67 on cervical lesions and its correlation with histopathology. J Med Sci Health. 2025;11(1):32–41
- Hanprasertpong J, Tungsinmunkong K, Chichareon S, Wootipoom V, Geater A, Buhachat R, et al. Correlation of p53 and Ki-67 (MIB-1) expressions with clinicopathological features and prognosis of early stage cervical squamous cell carcinomas. Journal of Obstetrics and Gynaecology Research 2010;36:572–80
- Vasilescu F, Ceausu M, Tanase C, Stanculescu R, Vladescu T, Ceauşu Z. P53, p63 and Ki-67 assessment in HPV-induced cervical neoplasia. Romanian Journal of Morphology and Embryology 2009;50:357-61
- Horikoshi M, Kina K, Ishi K, Izumi H, Kunii Y, Nojima M. Correlation between human papilloma virus infection in cervical lesions and expression of p53, p21 proteins and Ki-67. The Japanese Journal of Clinical Pathology 2005;53:494-8.
- Societatea de Obstetrică şi Ginecologie din România, Colegiul Medicilor din România. Ghid clinic – Cancerul de col uterin. Revizuit 2024.
- Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019 Jun 10;37(17):1470-8
- Șerbănescu, L.; Rotar V.; Ionescu E.V.; Ciota A.E.; Mirea S.; Iopnescu P.; Costea A.C. The role of Kegel exercises in reducing involuntary loss of urine in overactive bladder and mixed urinary incontinence. Balneo and PRM Research Journal, 2024, 15(4), 757.
- Șerbănescu, L.; Rotar, V.; Brezeanu, D.; Mirea, S.; Ionescu, E. V.; Ionescu, P. Evaluating the Efficacy of Combined Intravaginal Estriol Therapy and Kegel Exercises in Managing Menopausal Atrophic Vulvovaginitis. Clin Pract, 2025, 15(1), 20.
Language: English
Page range: 125 - 134
Published on: Jun 13, 2026
Published by: Ovidius University of Constanta
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Laura-Andra Petrica, Mariana Aşchie, Mariana Deacu, Georgeta Camelia Cozaru, Anca Florentina Mitroi, Lucian Şerbănescu, Gabriela Izabela Băltăţescu, Ana Maria Creţu, published by Ovidius University of Constanta
This work is licensed under the Creative Commons Attribution 4.0 License.